IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major healthcare investor conferences in June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Details
News Market Reaction – IDYA
The recorded move for IDYA in the trading session of this news was +6.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
2025 Jefferies Global Healthcare Conference
Wednesday, June 4th, 2025 at 8:10 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology
Goldman Sachs 46th Annual Global Healthcare Conference 2025
Monday, June 9th, 2025 at 10:40 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology
A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-june-2025-investor-relations-events-302469231.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.